Evidence of meeting #27 for Science and Research in the 45th Parliament, 1st session. (The original version is on Parliament’s site, as are the minutes.) The winning word was institutions.

A recording is available from Parliament.

On the agenda

Members speaking

Before the committee

Sheila Jasanoff  Pforzheimer Professor of Science and Technology Studies, Harvard University, As an Individual
Normand  President and Chief Executive Officer, Association des collèges et universités de la francophonie canadienne
O'Neil  Vice-President, Research and Innovation, Simon Fraser University

Maxime Blanchette-Joncas Bloc Rimouski-Neigette—Mitis—Matapédia—Les Basques, QC

Thank you, Madam Chair.

I would like to extend my greetings to the witnesses who joined us for this important study.

Ms. Jasanoff, in The Fifth Branch, you show that scientific expertise serves as a form of structuring power in democracies. In a Canadian parliamentary system, how should institutions regulate this function in order to preserve both its independence and its democratic responsibility?

11:30 a.m.

Pforzheimer Professor of Science and Technology Studies, Harvard University, As an Individual

Professor Sheila Jasanoff

Thank you for that question, and thank you for paying attention to my now decades-old work.

I think representation and recursion are the two variables that I consider most important. One of the things we have discovered is that when scientists get together and decide what is relevant to their review processes, often a set of blinders descends. There's disciplinary narrowing of the field of vision of the review process. One of the ways in which the National Research Council has tried to get away from that kind of narrowing is to ask somebody to coordinate the review process who is not specifically a member of the group producing the results.

In broad public review processes, Parliament or Congress can serve that purpose, to some extent. As you know, all our agencies are accountable for showing up before relevant congressional committees. That breadth of representation, which, for example, in the Canadian context would take language sensitivities and minority position sensitivities into account, would be one way of ensuring representation.

The other point is that the perfect should not be made the enemy of the good. No review process will be guaranteed to produce truth positions. Having recurrent review processes that come back—for example, when there's a large centre grant, having it reviewed with site visits at various points during its operations—and keeping that in mind will take care of some of the temporality issues mentioned by Dr. O'Neil in terms of science's ability to deliver. It doesn't happen all of a sudden, where yesterday you didn't know the truth and tomorrow you know.

Maxime Blanchette-Joncas Bloc Rimouski-Neigette—Mitis—Matapédia—Les Basques, QC

The government funds, produces and assesses scientific expertise within a single administrative apparatus. In your opinion, could this lead to a concentration of functions? If so, is institutional separation necessary to ensure the credibility of the system?

11:35 a.m.

Pforzheimer Professor of Science and Technology Studies, Harvard University, As an Individual

Professor Sheila Jasanoff

As you probably know, the question of what is independence is itself being heavily debated in the U.S. at the moment. Certain matters are before the courts and in the docket of the Supreme Court. We won't know what some of those answers are. From my academic point of view, independence is often a rhetoric and not a reality. Better than independence is seeking an internal diversity of views in whichever forum will have the ultimate say. We in America are in the unfortunate position at the moment of having polarization rather than representation across the spectrum. These are things we have to deal with.

I believe your problems in Canada are not quite the mirror of ours, fortunately. Perhaps you have procedural ways of getting around the black and white “this is right and this is wrong” position into which we have managed to start some of our research evaluations.

Maxime Blanchette-Joncas Bloc Rimouski-Neigette—Mitis—Matapédia—Les Basques, QC

You argued that accountability can't necessarily be limited to formal audits. In your opinion, what criteria would help assess whether a federal scientific agency is really acting in the public interest?

11:35 a.m.

Pforzheimer Professor of Science and Technology Studies, Harvard University, As an Individual

Professor Sheila Jasanoff

This is a very difficult question. Normally, if you go to a surgeon and you want surgery done, you come away with the problem cured or not. In federal science policy and in regulatory science policy, the results are seldom that quick to emerge.

I think one has to have a multipronged criterion. Emergency response cannot be held to the same standards as whether or not cancer research policy delivers the goods. This morning we've already talked about different kinds of criteria, and there was a question raised: Is research getting from bench to bedside? It is one kind of indicator, but it would not be the right kind of indicator for measuring whether emergency responses are working or whether climate change policies are working. I think one has to settle for a somewhat sector-specific approach to accountability issues. These are continually being revisited.

This is a point that I would make: It's not that in a thriving democracy like Canada the research policies have been sitting still, with no attention to these matters. One should pay attention to the historicity of these processes and what is being learned along the way.

The Chair Liberal Salma Zahid

MP Maxime Blanchette-Joncas, you have 10 seconds.

Maxime Blanchette-Joncas Bloc Rimouski-Neigette—Mitis—Matapédia—Les Basques, QC

If you could provide a written answer, Ms. Jasanoff, we would appreciate it.

If you had to identify a priority institutional reform to strengthen public confidence in science over the long term, what would it be?

11:35 a.m.

Pforzheimer Professor of Science and Technology Studies, Harvard University, As an Individual

Professor Sheila Jasanoff

I would not presume to state “one” thing, but I think what we need is simultaneous education of the public and openness by science to open itself up. I am a member of—

The Chair Liberal Salma Zahid

I'm sorry for interrupting. The time is up. If you can say it quickly, I can give you five or six seconds.

11:35 a.m.

Pforzheimer Professor of Science and Technology Studies, Harvard University, As an Individual

Professor Sheila Jasanoff

Public education about the process of science has to happen at the same time as accountability procedures are being developed.

The Chair Liberal Salma Zahid

Thank you.

Maxime Blanchette-Joncas Bloc Rimouski-Neigette—Mitis—Matapédia—Les Basques, QC

Madam Chair, is it possible to ask the witness for a written response, please?

The Chair Liberal Salma Zahid

Professor Jasanoff, would it be possible to provide a written response to Mr. Blanchette-Joncas' question?

11:40 a.m.

Pforzheimer Professor of Science and Technology Studies, Harvard University, As an Individual

Professor Sheila Jasanoff

I would be delighted to follow up.

The Chair Liberal Salma Zahid

Okay. Thanks a lot.

We will now proceed to MP Holman for five minutes.

Please go ahead.

Kurt Holman Conservative London—Fanshawe, ON

Thank you, Madam Chair.

Thank you to all the witnesses who are here today and are speaking before the science and research committee.

My first question is for you, Professor Jasanoff. A recent report from the Council of Canadian Academies notes declining living standards in Canada. If residents in places like London—Fanshawe do not see measurable economic benefits from federal research spending, does that signal a governance gap?

11:40 a.m.

Pforzheimer Professor of Science and Technology Studies, Harvard University, As an Individual

Professor Sheila Jasanoff

I think my colleague Dr. O'Neil has to some degree addressed this question of the gap. To the extent that I have done comparative research, it's clear that the venture capital system in the United States stands apart in the degree of risk it's willing to take and the degree of independence it has from supervision, in and of itself. It's not surprising for me to learn that American venture capitalists are jumping on Canadian IP, for instance.

I think it would be presumptuous of me to talk about how that gap should be addressed. You will probably know, on this committee, that the U.S. took a major step in 1980 by enacting the Bayh-Dole Act, which laid a responsibility on universities receiving public benefit to disseminate the results of their work and to actively seek out intellectual property ramifications from publicly funded research. Now, 40 years later, people are discerning pathologies in the systems. It turned universities to some extent into rent-seekers.

This is why I think one has to take a historical attitude to these things and recognize that the solution of today may need to be revisited 20 years from now, or even 10 years from now, because it will undoubtedly have unintended consequences.

11:40 a.m.

Conservative

Kurt Holman Conservative London—Fanshawe, ON

Canada was an early leader in artificial intelligence research, and yet we lag in AI commercialization. From your international perspective, is this primarily a governance failure, a market failure, or both?

11:40 a.m.

Pforzheimer Professor of Science and Technology Studies, Harvard University, As an Individual

Professor Sheila Jasanoff

I believe it's a governance failure and a market failure. We've already touched on the market failure in the sense that we have a corporate culture in America that allows risks to be publicly shouldered, whereas benefits are privately distributed. I think that creates a different kind of market from countries in which there is a commitment from the beginning that both risks and benefits should be more publicly distributed. I would be glad to provide additional information, but the constraints of time prevent me.

In terms of the governance failure, we're seeing in America the consequences of widespread, unregulated development of social media. We're coming back to some of these questions about how it affects health, particularly in vulnerable tranches of the population. The governance failure is not just that one is not encouraging the research. The governance failure could equally be that one has allowed research and application development and commercialization to run forward without foreseeing the consequences in time.

11:40 a.m.

Conservative

Kurt Holman Conservative London—Fanshawe, ON

You offered to give additional information to the committee that you don't have the time to give right now. If you could give that additional information to the committee, it would be greatly appreciated.

Mr. O'Neil, Canada excels at discovery but struggles to scale companies. Is this primarily a funding design problem or an incentive problem with academia, or is it a broader policy failure?

11:40 a.m.

Vice-President, Research and Innovation, Simon Fraser University

Dugan O'Neil

I think there's a little bit of each of the items you mentioned. It does start inside academia. We do have work to do to create the right internal incentive structures to have people strive to get their research out into the world in various ways. Universities are working hard on that now. Maybe traditionally, as my colleague Professor Jasanoff mentioned, the cultural conditions created by legislation 40 years ago in the United States created different conditions from what we have in Canada. There has been some university transformation happening in Canada in order to optimize the flow of ideas out of the university and into society, but we have found gaps in the ability of society to accept that flow.

What we find is that often the goal of entrepreneurs in Canada is to get big enough to sell their company to a large U.S. investor—

The Chair Liberal Salma Zahid

I'm sorry, Mr. O'Neil. The time is up for MP Holman.

MP Noormohamed, you have five minutes. Please go ahead.

Taleeb Noormohamed Liberal Vancouver Granville, BC

Thank you, Madam Chair.

Professor Jasanoff, I wonder if you could touch a little bit on your comment about the importance of the public receiving benefit from the innovation it helps to support. Could you talk a little bit more about that and why it's important, when investments are being made by the public sector into private sector corporations, that the public sector should see a return on that investment?

11:45 a.m.

Pforzheimer Professor of Science and Technology Studies, Harvard University, As an Individual

Professor Sheila Jasanoff

In a sense, you've answered your own question. I mean, we are paying tax dollars to fund the public till. We're doing that because we have entrusted the government to look after the public good. If, for instance, we're devoting $40 billion to biomedical research and it's not producing improvements across the board, then what are we doing with that funding?

Now, that said, one has to be extremely careful in how one calculates the benefits of scientific research, partly because of questions of time—research results are not immediate—but also partly because the focus may be erroneous. In the U.S. there has been an ongoing debate about whether we're funding researchers or research. That is, are we actually funding frontier knowledge that will be distributed across the board? Are we even funding the right sorts of things? If we have an overemphasis on silver bullet science, we are not investing in palliative care, but it may be that in the health care system, palliative care is the more important set of goals.

The solution to that is that the public has to have a role, because they often see things that the scientists themselves are too targeted and too tunnel-visioned to see.